

**A. Biographical and Bibliographic Information**

**IDENTIFYING DATA**

1. **Name:** Andrei Horia Iagaru

**B. ACADEMIC HISTORY**

**1. Colleges and Universities Attended**

Oct. 1994 - Nov. 2000 Carol Davila Medical School, Bucharest, Romania, M.D.

**2. Scholarships and Academic Honors (Excludes Post Degree Awards)**

1994 High School Valedictorian

1995, 1997, 1999, 2000 Carol Davila Excellence Scholarship/Dean's Honor List

1996 Education Secretary's Emeritus Scholarship

**3. Postdoctoral Residency and Training**

Jun. 2003 - Jun. 2004 Drexel University College of Medicine, Graduate Hospital, Department of Medicine (Intern)

Jul. 2004 – Jun. 2005 Keck School of Medicine of USC, LSC+USC Medical Center, Radiology Department, Division of Nuclear Medicine (Chief Resident)

Jul. 2005 – Jun. 2006 Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (Resident)

Jul. 2006 – Jun. 2007 Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (PET/CT Fellow)

**4. Certifications**

Oct. 2006 American Board of Nuclear Medicine

Feb. 2012 Radiography X-Ray Supervisor and Operator, ARRT

**C. EMPLOYMENT HISTORY**

**1. Academic Appointments**

Jul. 2004 – Jun. 2005 Clinical Instructor, Department of Radiology, Division of Nuclear Medicine Keck School of Medicine, University of Southern California

Jul. 2007 – Aug. 2010 Clinical Instructor, Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

Sep. 2010 – May 2014 Assistant Professor, Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

Jun. 2014 – present Associate Professor, Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

## D. PUBLIC AND PROFESSIONAL SERVICE

### 1. Committees and Appointments

2006 - present	Ad-Hoc Reviewer: <i>Radiology; American Journal of Roentgenology; Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Biology, Molecular Imaging and Biology; Annals of Nuclear Medicine; Nuclear Medicine Communications; Journal of Computer Assisted Tomography; Haematologica; British Journal of Cancer; Indian Journal of Cancer; American Journal of Neuroradiology</i>
2009 - present	Editorial Board: <i>PLoS ONE; American Journal of Nuclear Medicine and Molecular Imaging; Clinical Nuclear Medicine; Quantitative Imaging in Medicine and Surgery; World Journal of Radiology; Therapeutica</i>
2011 - 2014	Academic Editor: <i>PLoS ONE</i>
2009 - present	Member: <i>Radiology Residency Education Committee; Clinical Radiation Safety Committee; LPCH Transformation Project Committee - Nuclear Medicine /PET-CT;</i>
2011 - present	Program Director: <i>Stanford Nuclear Medicine Residency Program</i>
2012 - 2016	Co-Chief: <i>Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center</i>
2016 - present	Chief: <i>Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center</i>
2011 - 2016	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging Outreach Committee</i>
2012 - 2016	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging Targeted Radionuclide Therapy Working Group</i>
2013 - 2015	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging PET/MRI Task Force</i>
2011 - 2015	Ambassador to ASCO: <i>Society of Nuclear Medicine and Molecular Imaging</i>
2013 - 2015	Member: <i>Board of Directors, PET Center of Excellence (Society of Nuclear Medicine and Molecular Imaging)</i>
2012 - 2016	Member: <i>Society of Nuclear Medicine and Molecular Imaging Committee on Public Relations</i>
2013 - present	Member: <i>National Comprehensive Cancer Network Thyroid Cancer Panel</i>
2012 - present	Member: <i>Scientific Review Committee, Stanford Cancer Institute</i>
2007 - 2013	Associate Member: <i>Stanford Cancer Institute</i>
2013 - present	Member: <i>Stanford Cancer Institute</i>
2013 - present	Associate Member: <i>Canary Center at Stanford for Early Cancer Detection</i>
2014 - present	Co-Director: <i>PET/MRI Research Program at Stanford University</i>
2014 - present	Member: <i>Bio-X</i>
2017 - present	Associate Editor (Molecular Imaging): <i>Radiology</i>

## E. POST-DEGREE HONORS AND AWARDS

## 1. Honors and Awards

- 2007 Travel Grant Award, ACNP Annual Meeting: “ $^{18}\text{F}$  FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan?” (first author)
- 2008 Best Essay Award, ACNP Annual Meeting: “ $^{131}\text{I}$ -Tositumomab (Bexxar<sup>®</sup>) vs.  $^{90}\text{Y}$ -Ibritumomab (Zevalin<sup>®</sup>) in Refractory/Relapsed Non-Hodgkin’s Lymphoma” (first author)
- 2008 Best Essay Award, ACNP Annual Meeting: “ $^{18}\text{F}$  FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning?” (first author)
- 2008 Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author)
- 2008 Outstanding Teaching Award, Stanford Radiology Residency Program
- 2009 Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author)
- 2009 Image of the Year Award, Society of Nuclear Medicine (first author)
- 2009 Developmental Cancer Research Award, Stanford Cancer Center
- 2009 Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)
- 2010 Best Essay Award, ACNM Annual Meeting: “Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study” (first author)
- 2010 Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine (first author)
- 2011 Best Essay Award, ACNM Annual Meeting: “Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for  $^{18}\text{F}$  FDG PET/CT Surveillance?” (first author)
- 2011 Winner – Young Professional Tournament, 1<sup>st</sup> Sino-American Conference on Nuclear Medicine (first author)
- 2011 Radiopharmaceutical Sciences Council Travel Grant, SNM Annual Meeting (first author)
- 2011 Nuclear Oncology Council Young Investigator Award, 2<sup>nd</sup> Place, SNM Annual Meeting (first author)
- 2011 Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (senior author)
- 2013 Winner – Young Professional Tournament, 2<sup>nd</sup> Sino-American Conference on Nuclear Medicine (senior author)
- 2013 Fellow, American College of Nuclear Medicine
- 2013 Faculty Fellowship Award, Stanford Center at Peking University
- 2013 Stanford Faculty Fellows Program
- 2014 Poster Award, ACNM Annual Meeting: “Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT Evaluation of Sarcoma Patients” (senior author)

- |      |   |
|------|---|
| 2014 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)  |
| 2015 | Winner, ACNM/SNMMI Exchange Program Award: “A Prospective, Matched Comparison Study of SUV Values from non-TOF vs. TOF PET/CT Scanners” (senior author) |
| 2015 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)  |

## 2. Professional Membership Associations

- |      |   |
|------|---|
| 2005 | Society of Nuclear Medicine and Molecular Imaging |
| 2005 | Radiological Society of North America             |
| 2006 | World Molecular Imaging Society                   |
| 2007 | European Association of Nuclear Medicine          |
| 2007 | American College of Nuclear Medicine              |

## F. SCHOLARLY PUBLICATIONS

### 1. Peer-reviewed journal articles

1. Jadvar H, Bonyadlou S, **Iagaru A**, Colletti P. <sup>18</sup>F FDG PET/CT Demonstration of Salivary Glands Involvement in Sjogren’s Syndrome. *Clin Nucl Med*. 2005 Oct;30(10):698-9.
2. **Iagaru A**, Wassef H, Henderson R. Failed Atrial Septal Defect Repair versus Pulmonary Hypertension with Right Ventricular Failure. *Clin Nucl Med*. 2005 Nov;30(11):767-8.
3. **Iagaru A**, Siegel ME. Demonstration of a Right Inguinal Hernia Containing Urinary Bladder Diverticulum on Whole Body Bone Scan and Pelvic CT. *Eur J Nucl Med Mol Imaging*. 2006 Feb;33(2):234.
4. **Iagaru A**, Mari C, Segall G. <sup>18</sup>F FDG PET Evaluation of Bronchial Plasmacytoma, with CT and MRI Correlation. *Clin Nucl Med*. 2006 May;31(5):279-80.
5. **Iagaru A**, Quon A, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for <sup>18</sup>F FDG PET/CT? *Mol Imaging Biol*. 2006 Jul-Aug;8(4):212-7.
6. **Iagaru A**, Gamie S, Segall G. <sup>18</sup>F FDG PET Imaging of Urinary Bladder Oat Cell Carcinoma with Widespread Osseous Metastases. *Clin Nucl Med*. 2006 Aug;31(8):476-8.
7. **Iagaru A**, Henderson R. <sup>18</sup>F FDG PET/CT in the Follow-Up of Non-Ossifying Fibroma. *AJR Am J Roentgenol*. 2006 Sep;187(3):830-2.
8. **Iagaru A**, Hachamovitch R, Colletti PM, Wassef H. Ectopic Mediastinal Parathyroid Adenoma on <sup>99m</sup>Tc Sestamibi Myocardial Perfusion Scintigraphy. *J Nucl Cardiol*. 2006 Sep;13(5):719-21.
9. **Iagaru A**, Masamed R, Singer PA, Conti PS. <sup>18</sup>F FDG PET and PET/CT Diagnosis of Patients with Recurrent Papillary Thyroid Cancer. *Mol Imaging Biol*. 2006 Sep-Oct;8(5):309-14.
10. **Iagaru A**, Chawla SP, Menendez LR, Conti PS. <sup>18</sup>F FDG PET and PET/CT for Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. *Nucl Med Commun*. 2006 Oct;27(10):795-802.
11. **Iagaru A**, Quon A, McDougall IR, Gambhir SS. <sup>18</sup>F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. *Clin Nucl Med*. 2006 Dec;31(12):754-760.

12. **Igaru A**, McDougall IR. <sup>18</sup>F FDG PET/CT Demonstration of an Adrenal Metastasis in a Patient with Anaplastic Thyroid Cancer. *Clin Nucl Med*. 2007 Jan;32(1):13-5.
13. **Igaru A**, Quon A, Johnson D, Gambhir SS, McDougall IR. <sup>18</sup>F FDG PET/CT in the Management of Melanoma. *Mol Imaging Biol*. 2007 Jan-Feb;9(1):50-7.
14. **Igaru A**, Mari C, Gambhir SS. Follicular Dendritic Sarcoma within a Focus of Castleman's Disease. Serial <sup>18</sup>F FDG PET/CT in the Follow-Up of Recurrence with Histopathologic Confirmation. *Rev Esp Med Nucl*. 2007 Jan;26(1):40-5.
15. **Igaru A**, Masamed R, Keesara S, Conti PS. Breast MRI and <sup>18</sup>F FDG PET/CT in the Management of Breast Cancer. *Ann Nucl Med*. 2007 Jan;21(1):33-8.
16. **Igaru A**, Gamie S, Segall G. <sup>18</sup>F FDG PET Visualization of Urinary Leak Following Nephrostomy Tube Removal. *Clin Nucl Med*. 2007 Feb;32(2):168-169.
17. **Igaru A**, McDougall IR. Therapy of Thyrotoxicosis. *J Nucl Med*. 2007 Mar;48(3):379-89
18. **Igaru A**, Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer Recurrence with <sup>18</sup>F FDG PET and PET/CT. *Mol Imaging Biol*. 2007 Mar-Apr;9(2):72-7.
19. **Igaru A**, Quon A. Advances in Metabolic Imaging for Surgical Oncology. *Surg Oncol Clin N Am*. 2007 Apr;16(2):273-92.
20. **Igaru A**, Kalinyak J, McDougall IR. <sup>18</sup>F FDG PET/CT in the Management of Thyroid Cancer. *Clin Nucl Med*. 2007 Sep;32(9):690-5.
21. **Igaru A**, Chen X, Gambhir SS. Molecular Imaging Can Speed Up Anti-Angiogenic Drug Development. *Nat Clin Pract Oncol*. 2007 Oct;4(10):556-7.
22. Mitra ES, **Igaru A**, Quon A, Fischbein N. PET Imaging of Skull Base Neoplasms. *PET Clinics*. 2007 Oct;2(4):489-510.
23. **Igaru A**, Masamed R, Chawla S, Menendez L, Fedenko A, Conti PS. <sup>18</sup>F FDG PET and PET/CT Evaluation of Response to Neoadjuvant Chemotherapy in Musculoskeletal and Soft-Tissue Sarcomas. *Clin Nucl Med*. 2008 Jan;33(1):8-13.
24. **Igaru A**, Peterson D, Quon A, Dutta S, Twist C, Daghighian F, Gambhir SS, Albanese C. Case study: <sup>123</sup>I MIBG Mapping with Intraoperative Gamma Probe for Recurrent Neuroblastoma. *Mol Imaging Biol*. 2008 Jan-Feb;10(1):19-23.
25. **Igaru A**, Goris ML, Gambhir SS. Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma. *Radiol Clin North Am*. 2008 Mar;46(2):243-252.
26. **Igaru A**, Goris ML. Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on <sup>99m</sup>Tc-MDP bone scintigraphy confirmed by <sup>18</sup>F FDG PET/CT and bone marrow biopsy. *Eur J Nucl Med Mol Imaging*. 2008 Sep;35(9):1746.
27. **Igaru A**, Gambhir SS, Goris ML. <sup>90</sup>Y-Ibritumomab (Zevalin<sup>®</sup>) Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from <sup>111</sup>In-Ibritumomab Pre-Treatment Imaging. *J Nucl Med*. 2008 Nov;49(11):1809-1812.
28. **Igaru A**, Mitra ES, McDougall IR, Quon A, Gambhir SS. <sup>18</sup>F FDG PET/CT Evaluation of Patients with Ovarian Carcinoma. *Nucl Med Commun*. 2008 Dec;29(12):1046-51.
29. **Igaru A**, Wang, Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. <sup>18</sup>F FDG PET/CT Evaluation of Response to Therapy in Lymphoma: When is the Optimal Time for the First Re-evaluation Scan? *Hell J Nucl Med*. 2008 Sep-Dec;11(3):153-6.
30. **Igaru A**, Mitra ES, Yaghoubi S, Dick DW, Quon A, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail <sup>18</sup>F Fluoride and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot Phase Study. *J Nucl Med*. 2009 Apr;50(4):501-5.

31. **Iagaru A**, Kundu R, Jadvar H, Nagle D. Evaluation by  $^{18}\text{F}$  FDG PET of patients with anal squamous cell carcinoma. *Hell J Nucl Med*. 2009 Jan-Apr;12(1):26-8.
32. Mitra ES, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, **Iagaru A**. Efficacy of  $^{18}\text{F}$ -FDG PET/CT in the Evaluation of Patients with Recurrent Cervical Carcinoma. *Eur J Nucl Med Mol Imaging*. 2009 Dec;36(12):1952-9.
33. **Iagaru A**, Mitra ES, Ganjoo K, Knox SJ, Goris ML.  $^{131}\text{I}$ -Tositumomab (Bexxar<sup>®</sup>) vs.  $^{90}\text{Y}$ -Ibritumomab (Zevalin<sup>®</sup>) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma. *Mol Imaging Biol*. 2010 Apr;12(2):198-203.
34. Mitra ES, **Iagaru A**.  $^{18}\text{F}$  FDG PET and PET/CT for evaluating primary bone tumors. *PET Clin*. 2010 Jul;5(3):327-40.
35. Mansouri MA, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT Demonstration of Lymphohistiocytic Meningitis. *Clin Nucl Med*. 2010 Aug;35(8):633-4.
36. Lin F, **Iagaru A**. Current Concepts and Future Directions in Radioimmunotherapy. *Curr Drug Discov Technol*. 2010 Dec 1;7(4):253-62.
37. **Iagaru A**. (18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. *Am J Nucl Med Mol Imaging*. 2011;1(1):63-4.
38. Mitra ES, **Iagaru A**, Leung A. Case 166: Metastatic Left Pulmonary Artery Sarcoma. *Radiology*. 2011 Feb;258(2):645-648.
39. McDougall IR, **Iagaru A**. Thyroid Stunning: Fact or Fiction? *Seminars in Nuclear Medicine*. 2011 Mar;41(2):105-112.
40. **Iagaru A**, Mitra ES, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT in Cancers of the Head and Neck: What is the Definition of Whole-Body Scanning? *Mol Imaging Biol*. 2011 Apr;13(2):362-7.
41. Mitra ES, Goris ML, **Iagaru A**, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS. Pilot Pharmacokinetic and Dosimetric Studies of  $^{18}\text{F}$  FPPRGD<sub>2</sub>: A PET Radiopharmaceutical Agent for Imaging  $\alpha_v\beta_3$  Integrin Levels. *Radiology*. 2011 Jul;260(1):182-91.
42. Murphy JD, Chisholm KM, Daly ME, Wiegner EA, Truong D, **Iagaru A**, Maxim PG, Loo BW Jr, Graves EE, Kaplan MJ, Kong C, Le QT. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. *Radiother Oncol*. 2011 Dec;101(3):356-61.
43. Mosci C, **Iagaru A**. PET/CT Imaging of Thyroid Cancer. *Clin Nucl Med*. 2011 Dec;36(12):e180-5.
44. Sze DY, **Iagaru A**, Gambhir S, de Haan H, Reid T. Response to intraarterial oncolytic virotherapy with the Herpes virus NV-1020 evaluated by  $^{18}\text{F}$  fluorodeoxyglucose positron emission tomography and computed tomography. *Hum Gene Ther*. 2012 Jan;23(1):91-7.
45. Lin FI, Rao J, Mitra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, **Iagaru A**. Prospective Comparison of Combined  $^{18}\text{F}$  FDG and  $^{18}\text{F}$  NaF PET/CT vs.  $^{18}\text{F}$  FDG PET/CT Imaging for Detection of Malignancy. *Eur J Nucl Med Mol Imaging*. 2012 Feb;39(2):262-70.
46. **Iagaru A**, Mitra ES, Dick DW, Gambhir SS. Prospective Evaluation of  $^{99\text{m}}\text{Tc}$  MDP Scintigraphy,  $^{18}\text{F}$  NaF PET/CT and  $^{18}\text{F}$  FDG PET/CT for Detection of Skeletal Metastases. *Mol Imaging Biol*. 2012 Apr;14(2):252-9.
47. Guo H, Mosci C, **Iagaru A**. Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on  $^{18}\text{F}$  FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2012 Apr;39(4):729-30.
48. Mosci C, **Iagaru A**.  $^{18}\text{F}$  NaF PET/CT in the Assessment of Malignant Bone Disease. *PET Clinics*. 2012 Jul;7(3):263-74.
49. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, **Iagaru A**, Graves EE, Loo BW Jr, Le QT. Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1514-20.

50. Chu KP, Murphy JD, La TH, Krakow TE, **Iagaru A**, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT, Le QT. Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1521-7.
51. Mosci C, McDougall IR, Jeffrey RB, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT Demonstration of a Liver Metastasis in a Patient with Papillary Thyroid Cancer. *Clin Nucl Med*. 2012 Sep;37(9):e234-6.
52. Natarajan A, Gowrishankar G, Nielsen CH, Wang S, **Iagaru A**, Goris ML, Gambhir SS. Positron Emission Tomography of  $(64)\text{Cu}$ -DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL. *Mol Imaging Biol*. 2012 Oct;14(5):608-16.
53. Quon A, Dodd R, **Iagaru A**, de Abreu MR, Hennemann S, Neto JM, Sprinz C. Initial investigation of  $^{18}\text{F}$ -NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery. *Eur J Nucl Med Mol Imaging*. 2012 Nov;39(11):1737-44.
54. **Iagaru A**, Mitra ES, Dick DW, Mosci C, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS. Combined  $^{18}\text{F}$  FDG and  $^{18}\text{F}$  NaF PET/CT Scan for Evaluation of Malignancy: Results of an International Multi-Center Trial. *J Nucl Med*. 2013 Feb;54(2):176-83.
55. Delbeke D, Alessio A, **Iagaru A**. Second Sino-American Conference on Nuclear Medicine. *J Nucl Med*. 2013 Apr;54(4):15N-6N.
56. **Iagaru A**, Young PM, Mitra ES, Dick DW, Herfkens R, Gambhir SS. Pilot Prospective Evaluation of  $^{99\text{m}}\text{Tc}$ -MDP Scintigraphy,  $^{18}\text{F}$  NaF PET/CT,  $^{18}\text{F}$  FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. *Clin Nucl Med*. 2013 Jul;38(7):e290-6.
57. Nair VS, Keu KV, Luttggen MS, Kolatkar A, Vasanaawala M, Kuschner W, Bethel K, **Iagaru A**, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An Observational Study of Circulating Tumor Cells and  $(18)\text{F}$ -FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. *PLoS One*. 2013 Jul 5;8(7):e67733.
58. **Iagaru A**, Gambhir SS. Imaging Tumor Angiogenesis: The Road to Clinical Utility. *AJR Am J Roentgenol*. 2013 Aug;201(2):W183-91.
59. Kumar M, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT Demonstration of Diffuse Lymphohistiocytic Granulomatous Vasculitis. *Clin Nucl Med*. 2013 Aug;38(8):e329-30.
60. Lam MG, Louie JD, **Iagaru A**, Goris ML, Sze DY. Safety of Repeated Yttrium-90 Radioembolization. *Cardiovasc Intervent Radiol*. 2013 Oct;36(5):1320-8.
61. **Iagaru A**, Mosci C, Dick DW, Sathekge M, Lapa P, de Lima JM, Gambhir SS. Combined  $^{18}\text{F}$ -fluoride and  $^{18}\text{F}$ -FDG PET/CT: a response based on actual data from prospective studies. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1922-4.
62. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, **Iagaru A**, Ennen RE, Sze DY. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization. *Cardiovasc Intervent Radiol*. 2013 Dec;36(6):1536-47.
63. Lam MG, Goris ML, **Iagaru A**, Mitra ES, Louie JD, Sze DY. Prognostic Utility of  $^{90}\text{Y}$  Radioembolization Dosimetry Based on Fusion  $^{99\text{m}}\text{Tc}$ -Macroaggregated Albumin- $^{99\text{m}}\text{Tc}$ -Sulfur Colloid SPECT. *J Nucl Med*. 2013 Dec;54(12):2055-61.
64. Keu KV. **Iagaru A**. The Clinical Use of PET/CT in the Evaluation of Melanoma. *Methods Mol Biol*. 2014;1102:553-80.
65. Takehana C, Twist C, Mosci C, Mitra ES, Quon A, Gambhir SS, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT in the Management of Patients with Post-Transplant Lymphoproliferative Disorder. *Nucl Med Commun*. 2014 Mar;35(3):276-81.
66. Jones RP, **Iagaru A**.  $^{18}\text{F}$  NaF Brain Metastasis Uptake in a Patient with Melanoma. *Clin Nucl Med*. 2014 Oct;39(10):e448-50.

67. **Iagaru A**, Mosci C, Shen B, Chin FT, Mittra ES, Telli ML, Gambhir SS.  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. *Radiology*. 2014 Nov;273(2):549-59.
68. Mahapatra S, Chin CC, **Iagaru A**, Heerema-McKenney A, Twist CJ. Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation. *Pediatr Blood Cancer*. 2014 Nov;61(11):2107-9.
69. **Iagaru A**, Mittra E, Minamimoto R, Jamali M, Levin C, Quon A, Gold G, Herfkens R, Vasanawala S, Gambhir SS, Zaharchuk G. Simultaneous whole-body time-of-flight  $^{18}\text{F}$ -FDG PET/MRI: a pilot study comparing SUV<sub>max</sub> with PET/CT and assessment of MR image quality. *Clin Nucl Med*. 2015 Jan;40(1):1-8.
70. Jackson T, Sabbah N, **Iagaru A**.  $^{123}\text{I}$  Accumulation in Thoracic Neoesophagus Masking Residual Papillary Thyroid Cancer. *Clin Nucl Med*. 2015 Feb;40(2):e150-1.
71. Sampath S, Sampath S, Mosci C, Lutz A, Willmann JK, Mittra ES, Gambhir SS, **Iagaru A**. Detection of Osseous Metastases by Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT versus CT Alone. *Clin Nucl Med*. 2015 Mar;40(3):e173-7.
72. Natarajan A, Arksey N, **Iagaru A**, Chin FT, Gambhir SS. Validation of  $^{64}\text{Cu}$ -DOTA-Rituximab Injection Preparation Under Good Manufacturing Practices: A PET Tracer for Imaging of B-Cell Non-Hodgkin Lymphoma. *Mol Imaging*. 2015 Mar 1;14(0):1-11.
73. Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, Mittra ES, **Iagaru A**.  $^{18}\text{F}$ -Sodium Fluoride PET/CT in Oncology: An Atlas of SUVs. *Clin Nucl Med*. 2015 Apr;40(4):e228-31.
74. Smits ML, Elschot M, Sze DY, Kao YH, Nijsen JF, **Iagaru A**, de Jong HW, van den Bosch MA, Lam MG. Radioembolization Dosimetry: The Road Ahead. *Cardiovasc Intervent Radiol*. 2015 Apr;38(2):261-9.
75. Minamimoto R, Mosci C, Jamali M, Barkhodari A, Habte F, Jackson T, Mittra E, Gambhir SS, **Iagaru A**. Semiquantitative Analysis of the Biodistribution of the Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG Administration for PET/CT Imaging. *J Nucl Med*. 2015 May;56(5):688-94.
76. Lam MG, Banerjee A, Goris ML, **Iagaru A**, Mittra ES, Louie JD, Sze DY. Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. *Eur J Nucl Med Mol Imaging*. 2015 Jul;42(8):1192-201.
77. Harolds JA, Oates ME, Guiberteau MJ, Ghesani M, Scanlon MH, **Iagaru A**. New training pathways to dual certification in nuclear medicine and radiology. *J Nucl Med*. 2015 Jun;56(6):17N-18N.
78. Jackson T, Mosci C, von Eyben R, Mittra ES, Ganjoo K, Biswal S, Gambhir SS, **Iagaru A**. Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT in the Evaluation of Sarcoma Patients. *Clin Nucl Med*. 2015 Sep;40(9):720-4.
79. **Iagaru A**.  $^{18}\text{F}$ -Fluoride PET in the Assessment of Malignant Bone Disease. *J Nucl Med*. 2015 Oct;56(10):1476-7.
80. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, Chin FT, Gambhir SS, **Iagaru A**. Biodistribution of the  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET Radiopharmaceutical in Cancer Patients: An Atlas of SUV Measurements. *Eur J Nucl Med Mol Imaging*. 2015 Nov;42(12):1850-8.
81. **Iagaru A**, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS. Glioblastoma Multiforme Recurrence: An Exploratory Study of  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT. *Radiology*. 2015 Nov;277(2):497-506.
82. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution of the  $^{18}\text{F}$ -FPPRGD<sub>2</sub> PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. *Eur J Nucl Med Mol Imaging*. 2015 Nov;42(12):1850-8.
83. Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, **Iagaru A**. Prospective Comparison of  $^{99\text{m}}\text{Tc}$ -MDP Scintigraphy, Combined  $^{18}\text{F}$ -NaF and  $^{18}\text{F}$ -FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. *J Nucl Med*. 2015 Dec;56(12):1862-8.



84. Minamimoto R, Mitsumoto T, Miyata Y, Sunaoka F, Morooka M, Okasaki M, **Iagaru A**, Kubota K. Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image. Nucl Med Commun. 2016 Feb;37(2):162-70.
85. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanaawala S, Gambhir SS, **Iagaru A**. Pilot Comparison of <sup>68</sup>Ga-RM2 PET and <sup>68</sup>Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2016 Apr;57(4):557-62.
86. Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, **Iagaru A**. Pilot prospective evaluation of <sup>18</sup>F-FPPRGD<sub>2</sub> PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1047-55.
87. Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mitra ES, **Iagaru A**. Spectrum of <sup>68</sup>Ga-DOTA TATE Uptake in Patients with Neuroendocrine Tumors. 2016 Jun;41(6):e281-7.
88. Sonni I, **Iagaru A**. PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. PET Clin. 2016 Jul;11(3):261-72.
89. Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, **Iagaru A**. A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners. Clin Nucl Med. 2016 Jul;41(7):e323-6.
90. Guo HH, Moradi F, **Iagaru A**. Clinical Significance of Extra-skeletal CT Findings on <sup>18</sup>F-NaF PET/CT Performed for Osseous Metastatic Disease Evaluation. Nucl Med Commun. 2016 Sep;37(9):975-82.
91. Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, **Iagaru A**. Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. Mol Imaging Biol. 2016 Oct;18(5):776-81.
92. **Iagaru A**, Mitra E, Colletti PM, Jadvar H. Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):19S-24S.
93. Mansi R, Minamimoto R, Mäcke H, **Iagaru A**. Bombesin-Targeted PET of Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):67S-72S.

***Electronic publication ahead of print***

1. None

***In Press***

1. None

***Submitted***

1. Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, **Iagaru A**. Diagnostic <sup>123</sup>I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients with Papillary Thyroid Cancer: Implications for Clinical Management. J Nucl Med.

**2. Non-Peer Reviewed Journal Articles**

1. Mitra E, **Iagaru A**. Novel techniques in breast imaging. US Radiology. 2008 1(1):47-5.
2. Lin FI, **Iagaru A**. Updates on PET/CT and Thyroid Cancer. Applied Radiology. 2010 39(12):8-12.

**3. Book Chapters**

1. **Iagaru A.** Nuclear Medicine. In: Uzelac A, Davis R, eds. *Blueprints Radiology*, 2<sup>nd</sup> Edition. Lippincott Williams & Wilkins, Nov 2005.
2. **Iagaru A, McDougall IR.** Thyroid Imaging: Nuclear Medicine Techniques. In: Wass J, Shalet S, eds. *Oxford Textbook of Endocrinology and Diabetes*, 2<sup>nd</sup> Edition. Oxford University Press
3. Keu KV, **Iagaru A.** The Pre-Clinical and Clinical Use of PET/CT in the Evaluation of Melanoma. In: Thurin M, Marincola F, eds. *Molecular Diagnostics for Melanoma*. Humana Press.
4. **Iagaru A, McDougall IR.** PET/CT in Lymphoma of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2<sup>nd</sup> Edition. Humana Press.
5. **Iagaru A, McDougall IR.** PET/CT in Follicular Cancer Including Hürthle Cell Cancer. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2<sup>nd</sup> Edition. Humana Press.
6. **Iagaru A, McDougall IR.** PET/CT in Anaplastic Cancer of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2<sup>nd</sup> Edition. Humana Press.
7. **Iagaru A, McDougall IR.** PET/CT in Medullary Thyroid Cancer. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2<sup>nd</sup> Edition. Humana Press.

#### ***In Press***

1. Sonni I, Garibotto V, Das D, **Iagaru A**, Tarik F. Massoud. PET/MRI in Brain Tumors. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.
2. Sonni I, Baratto L, Freitag MT, Giesel F, Eiber M, **Iagaru A**. PET/MRI in Prostate Cancer. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.
3. Minamimoto R, Taviani V, Vasanaawala S, **Iagaru A**. Whole-body PET/MRI Applications in Oncology. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.

#### **4. Presentations**

##### ***Invited Presentations***

1. <sup>18</sup>F FDG PET/CT in the Management of Ovarian Carcinoma. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
2. <sup>18</sup>F FDG PET/CT Assessment of Patients with Thyroid Cancer. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
3. Radiation Therapy Planning for GI Cancers: When Can <sup>18</sup>F FDG PET/CT Evaluation Provide Useful Information? RSNA Annual Meeting, Chicago, IL. Nov 28, 2007.
4. Sarcomas: Classification, Diagnosis and Therapeutic Approaches, with an Emphasis on the Role of <sup>18</sup>F FDG PET/CT. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2008.
5. <sup>18</sup>F Sodium Fluoride: An Unfinished Business. MIPS Seminar Series, Stanford, CA. Nov 17, 2008.
6. Old Tracers, New Ideas: Clinical Research in Nuclear Medicine. Nuclear Medicine Grand Rounds. Stanford, CA. Nov 18, 2008.
7. The Physiology of <sup>18</sup>F FDG and Principles of PET Scanning. 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2009.
8. Vascular Tracer Activity: Disease or Not? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.

9. PET/CT as an Adjunctive Test for Infectious or Inflammatory Disease? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.
10. Bexxar<sup>®</sup> and Zevalin<sup>®</sup> Radioimmunotherapy in Non-Hodgkin Lymphomas. Stanford Nuclear Medicine Stampede, Stanford, CA. Mar 21, 2009.
11. Novel Strategies for PET/CT Imaging in Oncology. Medical Oncology Grand Rounds. Stanford, CA. Nov 10, 2009.
12. Updates on PET/CT and Thyroid Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 11, 2010.
13. <sup>99m</sup>Tc-MDP Scintigraphy vs. <sup>18</sup>F NaF PET/CT vs. <sup>18</sup>F FDG PET/CT for Detection of Skeletal Metastases. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2010.
14. Whole Body MRI vs. PET: Is PET Still Best for Oncology? 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
15. An Integrated Approach for the Early Detection of Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
16. Updates on PET/CT and Thyroid Cancer. Nuclear Medicine Grand Rounds. Stanford, CA. Apr 6, 2010.
17. Introduction to PET/CT. Hospital Mae de Deus Symposium, Porto Alegre, Brazil. Apr 26, 2010.
18. Lymphomas: What Can Nuclear Medicine Do for You? Medical Oncology Grand Rounds. Stanford, CA. Nov 16, 2010.
19. Imaging Angiogenesis: What Can Different Modalities Do? PET/CT in Angiogenesis Imaging. RSNA Annual Meeting, Chicago, IL. Dec 2, 2010.
20. <sup>18</sup>F FPPRGD<sub>2</sub>: A Novel PET Radiopharmaceutical for Imaging Breast Cancer. Breast Disease Management Group Grand Rounds. Stanford, CA. Apr 1, 2011.
21. Bexxar<sup>®</sup> and Zevalin<sup>®</sup> Radioimmunotherapy in Non-Hodgkin Lymphomas: Clinical Results. SNM Annual Meeting, San Antonio, TX. Jun 4, 2011.
22. Practical Considerations and Clinical Applications of Radioimmunotherapy. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 23, 2012.
23. Beyond FDG: Novel Clinical PET Radiopharmaceuticals. 17<sup>th</sup> Nuclear Medicine Annual Meeting, Coimbra, Portugal. Apr 25, 2012.
24. Novel PET Tracers and Their Future Use in Assessment of Response to Treatment. ASCO Annual Meeting, Chicago, IL. Jun 1-5, 2012 (Session Organizer and Co-Chair).
25. SPECT/CT in Thyroid and Parathyroid Diseases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
26. <sup>18</sup>F NaF PET/CT and <sup>18</sup>F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
27. Thyroid Imaging and Therapy for the Lay Person. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
28. Molecular Imaging in the Assessment and Follow-Up of Breast Cancer. Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
29. <sup>18</sup>F NaF PET/CT and <sup>18</sup>F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
30. Society of Nuclear Medicine & Molecular Imaging and Chinese Society of Nuclear Medicine 2<sup>nd</sup> Sino-American Conference, New Orleans, LA. Jan 23-27, 2013 (Organizer and Co-Chair).

31. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2013.
32. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. American Urological Association Annual Meeting, San Diego, CA. May 4-8, 2013. (Plenary Session)
33. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Medical Oncology Grand Rounds. Stanford, CA. May 14, 2013.
34. Update of Nuclear Medicine Imaging of Prostate Cancer. Urology Grand Rounds. Stanford, CA. Jun 4, 2013.
35. PET/CT in Clinical Practice: Evidence-based Use and Appropriateness Criteria. ASCO Annual Meeting, Chicago, IL. May 31 - Jun 4, 2013 (Session Organizer and Co-Chair; Speaker).
36. Molecular Imaging in Breast Cancer - Present and Future. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
37.  $^{18}\text{F}$  NaF PET/CT in the Evaluation of Skeletal Malignancy (Primary and Metastatic Disease). SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
38. PET/CT Imaging of Angiogenesis. Stanford University and Peking University Joint Symposium, Beijing. Apr 15, 2014 (Organizer; Speaker).
39. From Time-of-Flight PET/CT to Time-of-Flight PET/MRI: Stanford Experience. Chinese Society of Nuclear Medicine and CFMA Spring Meeting, Shenzhen, China. Apr 17-20, 2014 (Keynote Speaker).
40. PET/MRI: The Next Stop for Imaging Angiogenesis in Brain and Breast Cancers. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer; Speaker).
41. Bone Scintigraphy in the Management of Patients with Metastatic Castrate-Resistant Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer and Moderator; Speaker).
42. Differentiating Benign from Malignant Bone Disease: The Role of PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
43. Imaging Angiogenesis with PET: Radiopharmaceuticals, Opportunities, and Controversies. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
44. Clinical Translation of PET/MRI: Stanford Experience. Stanford University and Peking Union Medical College Joint Symposium, Beijing. Sep 14, 2014.
45. PET Imaging: From Bench to Bedside. St. Mary - Catholic University Molecular Imaging Symposium, Seoul, Korea. Sep 16, 2014.
46. Site Readiness and Challenges for Large Clinical Trials. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.
47. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.
48. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.
49. Clinical PET Innovations: Simultaneous TOF PET/MR and Fully-convergent PET reconstruction. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
50.  $^{18}\text{F}$  NaF: 2015 Updates. SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.
51. Current Status of  $^{18}\text{F}$  NaF PET/CT. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.

52. PET/MRI Case Review. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.
53. PET/MRI Future Directions: Oncology. ISMRM&SNMMI Joint Symposium at the SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015 (Session Organizer and Moderator; Speaker).
54. PET Imaging for Prostate Cancer in the United States: Beyond  $^{18}\text{F}$  FDG and  $^{18}\text{F}$  NaF. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.
55. Advanced Molecular Imaging and PET: A New Era of Personalized and Precision Medicine. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
56. From PET/CT to PET/MRI: Initial Clinical Experience at Stanford. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
57. PET/MRI at Stanford: Initial Clinical Experience and Future Directions. Peking Union Medical College International Forum on Frontier Technology, Beijing, China. Nov 15, 2015.
58. Anti-Angiogenesis Treatment: Can PET Predict Response Early and Accurately? SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
59.  $^{18}\text{F}$  NaF PET in Prostate Cancer: 2016 Updates. High Country Nuclear Medicine Annual Conference, Vail, CO. Feb 27 - Mar 2, 2016.
60. How to Get Away with PET+MRI. 4<sup>th</sup> Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.
61. Imaging the Expression of Gastrin Releasing Peptide Receptors in Prostate Cancer Using Ga-68 Labeled Antagonists. 4th Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.
62. The Current Status of PET+MRI in the United States, Its Future Outlook and What to be Expected. Osaka Advanced Imaging Medical Research Group Annual Meeting, Osaka, Japan. Feb 18-19, 2017.

***Other Presentations (selected)***

1. **Iagaru A**, Kundu R, Jadvar H, Nagle D. Does  $^{18}\text{F}$  FDG PET Change the Staging or Surgical Management of Anal Carcinoma? ACNP Annual Meeting, San Diego, CA. Jan 16-19, 2005.
2. **Iagaru A**. PET/CT Challenges. Conjoint Southern Pacific Society of Nuclear Medicine and Los Angeles Radiological Society Spring Meeting, Los Angeles, CA. May 14, 2005.
3. **Iagaru A**, Chawla SP, Menendez LR, Conti PS. The Role of  $^{18}\text{F}$  FDG PET and CT in Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. SNM Annual Meeting, Toronto, Canada. Jun 18-22, 2005.
4. **Iagaru A**, Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer with  $^{18}\text{F}$  FDG PET and PET/CT. RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 2, 2005.
5. **Iagaru A**, Quon A, Goris ML, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for  $^{18}\text{F}$  FDG PET/CT? AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.
6. **Iagaru A**, Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS. Comparison of Mammography, Breast MRI and  $^{18}\text{F}$  FDG PET/CT for Breast Cancer Detection. AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.
7. **Iagaru A**, Masamed R, Silberman H, Keesara S, Conti PS. The Role of  $^{18}\text{F}$  FDG PET/CT and Breast MRI in the Management of Breast Cancer. ASCO Annual Meeting, Atlanta, GA. Jun 2-6, 2006.
8. **Iagaru A**, Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT, Breast MRI and Mammography: Can Breast Cancer Be Reliably Detected? SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.

9. **Iagaru A**, Masamed R, Sankhala KK, Chawla S, Menendez L, Fedenko A, Conti PS. Post-Ifosfamide Therapy Inflammation in Musculoskeletal and Soft-Tissue Sarcomas: Evaluation with  $^{18}\text{F}$  FDG PET and PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
10. **Iagaru A**, Masamed R, Quan V, Singer PA, Conti PS. Detection of Occult Papillary Thyroid Cancer with  $^{18}\text{F}$  FDG PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
11. **Iagaru A**, Quon A, Johnson D, Goris ML, McDougall IR, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT in the Management of Melanoma. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
12. **Iagaru A**, Quon A, Goris ML, Gambhir SS, McDougall IR.  $^{18}\text{F}$  FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
13. **Iagaru A**, Quan V, Jadvar H, Conti PS. Sentinel Lymph Node Scintigraphy and  $^{18}\text{F}$  FDG PET/CT in the Management of Breast Cancer. ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
14. **Iagaru A**, Wang Y, Mari C, Rodriguez CA, Quon A, Goris ML, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan? ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
15. **Iagaru A**, Mitra E, Kaplan MJ, Quon A, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT in Squamous Cell Carcinoma of the Head and Neck: What is the Definition of Whole-Body Scanning? SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
16. **Iagaru A**, Mitra E, Quon A, Gambhir SS, McDougall IR.  $^{18}\text{F}$  FDG PET/CT Evaluation of Ovarian Cancer. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
17. **Iagaru A**, Zhu H, Mari C, Knox SJ, Goris ML.  $^{90}\text{Y}$ -Ibritumomab (Zevalin®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
18. **Iagaru A**, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. Comparison of Efficacy and Toxicity of Bexxar and Zevalin in the Management of Refractory Non-Hodgkin's Lymphoma. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
19. **Iagaru A**, McDougall IR.  $^{18}\text{F}$  FDG PET/CT in the Management of Papillary Thyroid Cancer, with an Emphasis on Thyroglobulin, TSH and Lesion SUVmax Values. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
20. **Iagaru A**, Quon A, Jacobs C, Marina N, McDougall IR, Gambhir SS. Osseous and soft tissue sarcomas: when can  $^{18}\text{F}$  FDG PET/CT evaluation provide useful information? EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
21. **Iagaru A**, Rodriguez CA, El-Maghraby T, Quon A, Gambhir SS, McDougall IR.  $^{18}\text{F}$  FDG PET/CT Evaluation of Patients with Cervical Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
22. **Iagaru A**, Mitra E, Le Q, Quon A, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT in Nasopharyngeal Carcinoma: What Do We Need to Scan? RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
23. **Iagaru A**, Mitra E, Quon A, Daniel B, Ikeda D, Herfkens R, McDougall IR, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT Evaluation of Patients with Breast Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
24. **Iagaru A**, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML.  $^{131}\text{I}$ -Tositumomab (Bexxar®) vs.  $^{90}\text{Y}$ -Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin's Lymphoma. ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
25. **Iagaru A**, Mitra E, Quon A, Gambhir SS.  $^{18}\text{F}$  FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning? ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
26. **Iagaru A**. Sarcomas: Classification, Diagnosis, and Therapeutic Approaches with an Emphasis on the Role of  $^{18}\text{F}$  FDG PET/CT. Northern California Chapter SNM Annual Meeting, Pleasanton, CA. Feb 28, 2008.

27. **Igaru A**, Mitra ES, Gambhir SS, Goris ML. Can <sup>111</sup>In-Ibritumomab Imaging Predict the Outcome of <sup>90</sup>Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin's Lymphoma (NHL)? SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.
28. Mitra ES, Quon A, McDougall IR, Gambhir SS, **Igaru A**. <sup>18</sup>F-FDG PET/CT in the Evaluation of Pediatric Sarcomas. SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.
29. **Igaru A**, Knox SJ, Goris ML. <sup>131</sup>I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.
30. **Igaru A**, Mitra ES, Quon A, Jacobs C, Marina N, Gambhir SS. <sup>18</sup>F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.
31. **Igaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail <sup>18</sup>F Fluoride and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
32. **Igaru A**, Gambhir SS. <sup>18</sup>F FDG PET/CT Evaluation of Response to Oncolytic Herpes Simplex Virus (NV 1020) Therapy in Patients with Colorectal Cancer Metastatic to the Liver. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
33. **Igaru A**, Knox SJ, Goris ML. <sup>131</sup>I-Tositumomab (Bexxar®) vs. <sup>90</sup>Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin's Lymphoma: Clinical Experience. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
34. **Igaru A**, Mitra ES, Dick DW, Quon A, Gambhir SS. Prospective Evaluation of <sup>99m</sup>Tc-MDP Scintigraphy, <sup>18</sup>F NaF PET/CT and <sup>18</sup>F FDG PET/CT for Detection of Skeletal Metastases. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
35. **Igaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Cocktail <sup>18</sup>F Fluoride and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
36. Mitra ES, Quon A, Gambhir SS, **Igaru A**. Efficacy of <sup>18</sup>F-FDG PET/CT for Breast Cancer. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
37. **Igaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Cocktail <sup>18</sup>F Fluoride and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy. WRSNM Annual Meeting, Monterey, CA. Oct 29-Nov 1, 2009.
38. **Igaru A**, Young P, Mitra ES, Quon A, Dick DW, Gambhir SS, Herfkens R. Prospective Evaluation of <sup>99m</sup>Tc-MDP Scintigraphy, <sup>18</sup>F NaF PET/CT, <sup>18</sup>F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. RSNA Annual Meeting, Chicago, IL. Nov 29-Dec 4, 2009.
39. **Igaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Combined <sup>18</sup>F NaF and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. ACNM/SNM Mid-Winter Meeting, Albuquerque, NM. Jan 27-29, 2010.
40. **Igaru A**, Mitra ES, Dick DW, Gambhir SS. Combined <sup>18</sup>F NaF and <sup>18</sup>F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.
41. **Igaru A**, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for <sup>18</sup>F FDG PET/CT Surveillance? EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.
42. Lin IF, Rao JE, Mitra ES, Gambhir SS, **Igaru A**. Prospective Comparison of Combined <sup>18</sup>F FDG and <sup>18</sup>F NaF vs. Conventional <sup>18</sup>F FDG PET/CT Imaging for Detection of Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 27-Dec 2, 2010.
43. **Igaru A**, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for <sup>18</sup>F FDG PET/CT Surveillance? ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.

44. Nguyen JQ, Davis K, Mitra ES, Quon A, Gambhir SS, Marina N, **Iagaru A**. Comparison of Clinical Utility of  $^{18}\text{F}$  FDG PET/CT and  $^{99\text{m}}\text{Tc}$  MDP Bone Scintigraphy in Patients with Ewing's Sarcoma and Other Forms of Sarcomas. ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.
45. **Iagaru A**, Mitra ES, Sathekge M, Prakash V, Iyer V, Dick D, Lapa P, Isidoro J, de Lima J, Gambhir SS. Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT: Initial Results of a Multi-Center Trial. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.
46. **Iagaru A**, Mosci C, Mitra ES, Shen B, Chin F, Chen X, Telli M, Gambhir SS.  $^{18}\text{F}$  FPPRGD<sub>2</sub> in Breast Cancer Subjects: A Novel PET Radiopharmaceutical for Imaging  $\alpha_v\beta_3$  Integrin Levels. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.
47. Nguyen JQ, Davis K, Mitra ES, Gambhir SS, Marina N, **Iagaru A**. Clinical Utility of  $^{18}\text{F}$  FDG PET/CT and  $^{99\text{m}}\text{Tc}$  MDP Bone Scintigraphy in Patients with Ewings Sarcoma and Other Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
48. Takehana C, Twist C, Mitra E, Quon A, Gambhir SS, **Iagaru A**. Post-Transplant Lymphoproliferative Disorder: Is There a Role for  $^{18}\text{F}$  FDG PET/CT? RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
49. Sampath SC, Sampath SC, Lutz AM, Willmann JK, Mitra ES, Gambhir SS, **Iagaru A**. The Value of Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT Versus CT Alone for Evaluation of Osseous Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
50. Mosci C, Akatsu H, Basina M, Dosiou C, **Iagaru A**. The role of diagnostic  $^{123}\text{I}$  whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
51. Davidzon G, Wakelee H, Neal J, Mitra ES, Quon A, **Iagaru A**. Utility of  $^{18}\text{F}$  FDG PET/CT in patients with advanced thymic neoplasms. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
52. Sampath SC, Sampath SC, Lutz A, Willmann JK, Mitra ES, Gambhir SS, **Iagaru A**. Evaluation of NaF PET/CT, FDG PET/CT, combined NaF/FDG PET/CT and CT alone for detection of bone metastases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
53. Takehana C, Mitra ES, Quon A, Gambhir SS, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
54. **Iagaru A**, Mosci C, Mitra ES, Shen B, Chin F, Fischbein N, Gambhir SS.  $^{18}\text{F}$  FPPRGD<sub>2</sub> in GBM: Imaging  $\alpha_v\beta_3$  integrin levels as a biomarker of disease recurrence. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
55. Keu KV, Mitra ES, Quon A, **Iagaru A**. Metabolic Imaging Patterns of Complete Local Response to Chemoradiation in Patients with Nasopharyngeal Carcinoma: A Review. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
56. Keu KV, Nair VS, Mitra ES, Quon A, Gambhir SS, **Iagaru A**. The Impact of Partial Volume Correction in the Evaluation of Solitary Pulmonary Nodules by FDG PET/CT in a Population at Intermediate Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
57. Keu KV, Mitra ES, Quon A, Gambhir SS, **Iagaru A**. Feasibility of Limited Thoracic FDG PET/CT for the Evaluation of Solitary Pulmonary Nodules in Patients With Intermediate and High Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
58. **Iagaru A**, Mosci C, Mitra ES, Shin B, Chin F, Gambhir SS.  $\alpha_v\beta_3$  Integrins as a Biomarker of Disease Recurrence in Glioblastoma Multiforme: Initial Clinical Results Using  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
59. **Iagaru A**, Mosci C, Akatsu H, Basina M, Dosiou C, I. Ross McDougall. Post-Surgical  $^{131}\text{I}$  Ablation in Patients with Papillary Thyroid Cancer: The Role of Diagnostic  $^{123}\text{I}$  Whole Body Scan. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.



60. Davidzon G, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution and Kinetics of  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT in the Evaluation of Suspected Recurrence in Glioblastoma Multiforme. ACNM/SNMMI Mid-Winter Meeting, New Orleans, LA. Jan 24-27, 2013.
61. Keu KV, Mittra E, Quon A, **Iagaru A**. Pre-Treatment  $^{18}\text{F}$  FDG PET/CT Findings Can Not Predict Late Recurrence of Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
62. Keu KV, Mittra E, Quon A, **Iagaru A**. The Value of Post-Therapy  $^{18}\text{F}$  FDG PET/CT Surveillance Scans in the Detection of Recurrent Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
63. Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, **Iagaru A**. Implications of  $^{123}\text{I}$  Whole Body Scan Pre-Ablation of Thyroid Remnant in Papillary Thyroid Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
64. Mosci C, Ganjoo K, Norton J, Mittra E, Quon A, **Iagaru A**. The Value of  $^{18}\text{F}$  FDG PET/CT in the Evaluation of Soft Tissue Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
65. Mosci C, Marina N, Ganjoo K, Mohler D, Avedian R, Mittra E, Quon A, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT and Dedicated CT in the Evaluation of Bone Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
66. Mosci C, Marina N, Mittra E, Quon A, **Iagaru A**.  $^{18}\text{F}$  FDG PET/CT Evaluation of Pediatric Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
67. Davidzon G, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution and Kinetics of  $^{18}\text{F}$  FPPRGD<sub>2</sub> in Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
68. Hope T, Keu KV, Robb F, Herfkens R, **Iagaru A**. Effect of Anterior Body MRI Coils on PET Acquisitions and Evaluation of a Novel Minimally Attenuating PET/MR Coil. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
69. **Iagaru A**, Davidzon G, Mosci C, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of the Novel PET/CT Radiopharmaceutical  $^{18}\text{F}$  FPPRGD<sub>2</sub> in Patients with Non-Small Cell Lung Cancer. WMIS Annual Congress, Savannah, GA. Sep 18-21, 2013.
70. **Iagaru A**, Davidzon G, Mosci C, Kumar M, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical  $^{18}\text{F}$  FPPRGD<sub>2</sub>. EANM Annual Congress, Lyon, France. Oct 19-23, 2013.
71. Keu KV, Lutchman G, Quon A, Mittra ES, **Iagaru A**. The Role of  $^{99\text{m}}\text{Tc}$ -MDP Bone Scintigraphy in the Workup of Patients with Hepatocellular Carcinoma. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.
72. Keu KV, Twist C, Quon A, Mittra ES, **Iagaru A**. Semi-quantitative Evaluation of Neuroblastoma Tumor Burden Using  $^{123}\text{I}$  mIBG and  $^{18}\text{F}$  FDG PET/CT. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.
73. Jackson T, Mosci C, von Eyben R, Mittra ES, Ganjoo K, Biswal S, Gambhir SS, **Iagaru A**. Combined  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT in the Evaluation of Sarcoma Patients. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Feb 6-9, 2014.
74. **Iagaru A**, Mosci C, Jamali M, Minamimoto R, Mittra ES, Shin B, Chin F, Gambhir SS.  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT Evaluation Of Patients With Suspected Recurrence Of Glioblastoma Multiforme. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
75. **Iagaru A**, Mittra ES, Zaharchuk G, Prost RW, Elekes A, Anderson J, Bobb C, Lahrman J, Gold GE, Gambhir SS.  $^{18}\text{F}$  FDG SUVmax Values in Normal Tissues and Malignant Lesions from the First Time-of-Flight Whole-Body PET/MRI Scanner: Comparison with Values from PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
76. Castaneda P, Leonard Z, Wen M, Kwofie J, Mittra ES, **Iagaru A**. Initial Experience with  $^{223}\text{Ra}$  Vial Delivery (Alpharadin<sup>®</sup>) vs. Unit-Dose Delivery (Xofigo<sup>®</sup>). SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.

77. **Igaru A**, Mosci C, Jamali M, Loening A, Mitra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
78. **Igaru A**, Mosci C, Jamali M, Loening A, Mitra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.
79. **Igaru A**, Jamali M, Minamimoto R, Mitra ES, Gold GE, Vasanawala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.
80. **Igaru A**, Mosci C, Keu KV, Mitra ES, Hancock S, Pachynski R, Srinivas S, Gambhir SS  $^{18}\text{F}$  NaF and  $^{18}\text{F}$  FDG PET/CT for Evaluation of Prostate Cancer Patients. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.
81. **Igaru A**, Jamali M, Minamimoto R, Mitra ES, Gold GE, Vasanwala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.
82. **Igaru A**, Mosci C, Jamali M, Barkhodari A, Minamimoto R, Loening A, Mitra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.
83. Sabbah N, Jackson T, Mosci C, Jemali M, Minamimoto R, Quon A, **Igaru A**. Characterization of  $^{18}\text{F}$ -NaF Uptake in Normal Bone, Bone Metastases, Degenerative Changes and Extra-Skeletal Tissues: An Atlas of Standardized Uptake Values. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
84. Minamimoto R, **Igaru A**, Jamali M, Holley D, Vasanawala S, Herfkens, R Sawyer AM, Glover G, Gambhir SS, Zaharchuk G. Whole-body Simultaneous Time-of-Flight PET-MRI: Initial Clinical Experience. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
85. Thompson H, Jamali M, Minamimoto R, Barkhodari A, Quon A, Mitra ES, **Igaru A**. SUV Values in Cancer Lesions: A Prospective, Matched Comparison of Data from Non-TOF vs. TOF PET/CT Scanners. ACNM/SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.
86. Minamimoto R, Levin CS, Jamali M, Barkhodari A, Holley D, Zaharchuk G, **Igaru A**. The potential of TOF PET-MRI for reducing artifacts in PET images. 4th Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.
87. **Igaru A**, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasanawala SS. Imaging Patients with Breast and Prostate Cancers Using Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG and TOF simultaneous PET/ MRI. 4<sup>th</sup> Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.
88. **Igaru A**, Minamimoto R, Mosci C, Jamali M, Barkhodari A, Loening AM, Taviani V, Mitra E, Gambhir SS, Vasanawala S. Prospective evaluation of  $^{99\text{m}}\text{Tc}$  MDP scintigraphy,  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT and WBMRI in patients with breast and prostate cancers. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
89. **Igaru A**, Minamimoto R, Jamali M, Barkhodari A, Obara P, Loening AM, Taviani V, Mitra E, Gambhir SS, Vasanawala S. Imaging patients with breast and prostate cancers using combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG and TOF simultaneous PET/MRI. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
90. Lantos J, Mitra E, Levin CS, **Igaru A**. Standard OSEM vs. regularized PET image reconstruction: qualitative and semi-quantitative comparison. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
91. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mitra E, Shen B, Chin F, Gambhir SS, **Igaru A**.  $^{18}\text{F}$ -FPPRGD<sub>2</sub> PET as a Surrogate Biomarker of Integrin  $\alpha_v\beta_3$  Expression Before and After Anti-angiogenesis Treatment. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.

92. **Iagaru A**, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasanaawala SS. Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG and TOF simultaneous PET/ MRI in patients with breast and prostate cancer. WMIS Annual Congress, Honolulu, HI. Sep 2-5, 2015.
93. Xu G, Minamimoto R, Quon A, Mittra E, **Iagaru A**. Semi-quantitative assessment of  $^{18}\text{F}$  FDG uptake in the normal skeleton using simultaneous PET/MRI: initial comparison to PET/CT in 50 patients. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
94. Minamimoto R, Jamali M, Barkhodari A, Holley D, Zaharchuk G, Levin C, **Iagaru A**. Improvements in PET Image quality from TOF PET/MRI. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
95. **Iagaru A**, Lantos J, Mittra EM, Levin C. Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Semi-Quantitative Comparison. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
96. Minamimoto R, Loening A, Obara P, Taviani V, Gambhir SS, Vasanaawala S, **Iagaru A**. Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG and TOF simultaneous PET/ MRI: One-Stop Shop Staging of Patients with Breast and Prostate Cancers. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
97. **Iagaru A**, Minamimoto R, Schneider B, Chin FT, Mittra ES, Taviani V, Vasanaawala S, Mueller A, Berndt M, Stephens A, Gambhir SS. Pilot Prospective Evaluation of  $^{68}\text{Ga}$ -DOTA-Bombesin ( $^{68}\text{Ga}$ -RM2 or  $^{68}\text{Ga}$ -Bombesin) with TOF PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.
98. Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanaawala SS, Iagaru A. Imaging Patients with Breast and Prostate Cancers Using Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG and TOF simultaneous PET/ MRI. RSNA Annual Meeting, Chicago, IL. Nov 29 - Dec 5, 2015.
99. **Iagaru A**, Minamimoto R, Hancock S, Mittra ES, Loening A, Vasanaawala S, Gambhir SS.  $^{68}\text{Ga}$ -DOTA-Bombesin ( $^{68}\text{Ga}$ -RM2 or  $^{68}\text{Ga}$ -Bombesin) PET vs.  $^{68}\text{Ga}$ -PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ASCU GU Symposium, San Francisco, CA. Jan 7-9, 2016.
100. **Iagaru A**, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanaawala S. Biochemically Recurrent Prostate Cancer:  $^{68}\text{Ga}$ -DOTA-Bombesin ( $^{68}\text{Ga}$  -RM2 or  $^{68}\text{Ga}$  -Bombesin) PET/MRI Is Superior to Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
101. **Iagaru A**, Minamimoto R, Loening A, Vasanaawala S, Gambhir SS.  $^{68}\text{Ga}$ -DOTA-Bombesin ( $^{68}\text{Ga}$ -RM2 or  $^{68}\text{Ga}$ -Bombesin) PET vs.  $^{68}\text{Ga}$ -PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
102. Wu F, Jamali M, Hatami N, Sonni I, Baratto L, Guo HH, Quon A, Mittra E, **Iagaru A**.  $^{99\text{m}}\text{Tc}$ -MDP scintigraphy vs.  $^{18}\text{F}$ -NaF PET/CT for detection of skeletal metastases. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.
103. **Iagaru A**, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanaawala S. Biochemically recurrent prostate cancer:  $^{68}\text{Ga}$ -RM2 (formerly known as  $^{68}\text{Ga}$ -Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.
104. Deller T, Khalighi MM, Lantos J, Gulaka P, **Iagaru A**. Evaluation of improved scatter correction with highly targeted  $^{68}\text{Ga}$ -labeled radiopharmaceuticals. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.
105. **Iagaru A**, Sonni I, Minamimoto R, Loening A, Vasanaawala S.  $^{68}\text{Ga}$ -RM2 PET/MRI Evaluation of Gastrin-Releasing Peptide Receptors Status in Biochemically Recurrent Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.
106.  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG simultaneous PET/ MRI with TOF in patients with breast and prostate cancers. Sonni I, Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanaawala SS, **Iagaru A**. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.

107. Sonni I, Minamimoto R, Loening A, Vasanawala S, **Iagaru A**. <sup>68</sup>Ga-RM2 PET/MRI in biochemically recurrent prostate cancer: a comparison with conventional imaging RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 3, 2016.
108. Harrison C, Sonni I, Loening A, Vasanawala S, **Iagaru A**. <sup>68</sup>Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Phoenix, AR. Jan 18-22, 2017.

## G. Research

### 1. Active

Source:	Department of Defense
Title:	<sup>68</sup> Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
Role:	Principal Investigator
Period Covered:	2016 - 2019
Goal:	To evaluate a new gastrin releasing peptide receptor PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer
Source:	GE Healthcare
Title:	Combined <sup>18</sup> F NaF/ <sup>18</sup> F FDG PET/MRI for Skeletal Metastases Detection
Role:	Principal Investigator
Period Covered:	2014 - 2018
Goal:	To evaluate PET and MRI in detection of skeletal metastases
Source:	GE Healthcare
Title:	<sup>18</sup> F FPPRGD <sub>2</sub> PET/MRI in Patients with Cancer Receiving Anti-Angiogenesis Treatment
Role:	Principal Investigator
Period Covered:	2014 - 2018
Goal:	To evaluate <sup>18</sup> F FPPRGD <sub>2</sub> PET/MRI in various cancers
Source:	GE Healthcare
Title:	PET/MRI of Cardiac Amyloid
Role:	Principal Investigator
Period Covered:	2014 - 2018
Goal:	To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac amyloid
Source:	GE Healthcare
Title:	PET/MRI of Cardiac Sarcoid
Role:	Principal Investigator
Period Covered:	2016 - 2018
Goal:	To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac sarcoid
Source:	GE Healthcare
Title:	PET/MRI of Cardiac Amyloid
Role:	Principal Investigator
Period Covered:	2014 - 2018
Goal:	To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac amyloid
Source:	GE Healthcare
Title:	<sup>68</sup> Ga-PSMA PET/MRI in Patients with Newly Diagnosed Intermediate and High Risk Prostate Cancer
Role:	Principal Investigator
Period Covered:	2016 - 2018
Goal:	To evaluate a new prostate specific membrane antigen PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer
Source:	GE Healthcare

Title: External Validation of the Next Generation PET/CT System  
Role: Principal Investigator  
Period Covered: 2016 - 2017  
Goal: To test a novel PET/CT scanner

Source: GE Healthcare  
Title: Comparison of Standard PET/CT Versus Digital PET/CT  
Role: Principal Investigator  
Period Covered: 2016 - 2019  
Goal: To compare a novel PET/CT scanner versus standard PET/CT

Source: Bayer Healthcare  
Title: Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Ra-223 in mCRPC Patients  
Role: Principal Investigator  
Period Covered: 2015 - 2018  
Goal: To test a novel diagnostic approach for evaluation of response to therapy of bone metastases

## 2. Completed

Source: ART  
Title: Adjunctive Efficacy Study of the SoftScan Optical Breast Imaging System  
Role: Co-Investigator  
Period Covered: 2006 - 2009  
Goal: To investigate a novel optical scanner for detection of malignant breast lesions

Source: Genentech  
Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab  
Role: Co-Investigator  
Period Covered: 2007 - 2009  
Goal: To develop a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Stanford Cancer Institute  
Title:  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT in Patients with Breast Cancer  
Role: Principal Investigator  
Period Covered: 2010 - 2011  
Goal: To evaluate  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT in breast cancer

Source: Ivy Foundation  
Title:  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT,  $^{18}\text{F}$  FDG PET/CT and MRI Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent Glioblastoma Multiforme  
Role: Co-Investigator  
Period Covered: 2010 - 2016  
Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with recurrent GBM

Source: NIH  
Title: Monitoring Response to Targeted Therapy in Non-Small Cell Lung Cancer using  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT and *In-Vitro* Diagnostics  
Role: Co-Investigator  
Period Covered: 2010 - 2015  
Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with NSCLC

Source: GE Healthcare  
Title: Comparison of Combined  $^{18}\text{F}$  NaF/ $^{18}\text{F}$  FDG PET/CT and WBMRI for Skeletal Metastases Detection  
Role: Principal Investigator  
Period Covered: 2012 - 2014  
Goal: To evaluate PET/CT and WBMRI in detection of skeletal metastases

Source: Stanford Cancer Institute  
Title:  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT in Patients with Sarcoma  
Role: Principal Investigator  
Period Covered: 2012 - 2013  
Goal: To evaluate  $^{18}\text{F}$  FPPRGD<sub>2</sub> PET/CT in angiosarcoma

Source: Department of Radiology, Stanford University  
Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab  
Role: Principal Investigator  
Period Covered: 2012 - 2013  
Goal: To test a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Bayer Healthcare  
Title: Alpharadin in Castration-Resistant (Hormone Refractory) Prostate Cancer Patients with Bone Metastases  
Role: Principal Investigator  
Period Covered: 2012 - 2014  
Goal: To test a novel radiopharmaceutical for therapy of bone metastases

Source: Piramal Imaging, GmbH  
Title:  $^{68}\text{Ga}$ -RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging  
Role: Principal Investigator  
Period Covered: 2015 - 2016  
Goal: To evaluate a new gastrin releasing peptide receptor PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer